Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Aevi Genomic Medicine

Aevi Genomic Medicine
2000 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
GNMX STOCK SYMBOL
1 INVESTMENTS
$0.15 SHARE PRICE (As of Wednesday Closing)
Description

Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.

Formerly Known As
Biogenics, MedGenics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 435 Devon Park Drive
  • Suite 715
  • Wayne, PA 19087
  • United States

+1 (610) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aevi Genomic Medicine’s full profile, request a free trial.

Aevi Genomic Medicine Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.11 - $1.23 $9.5M $0.16 -$0.29 729K 64.8M

Aevi Genomic Medicine Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 6,278 25,735 56,239 144,910
Revenue 0 0 0 0
EBITDA (19,206) (30,916) (34,621) (41,615)
Net Income (19,152) (30,775) (34,714) (41,904)
Total Assets 2,796 12,277 34,761 40,561
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aevi Genomic Medicine Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Aevi Genomic Medicine‘s full profile, request access.

Request full access to PitchBook

Aevi Genomic Medicine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Aevi Genomic Medicine‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Aevi Genomic Medicine Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 09-Sep-2015 000000000000000000 00000 Drug Discovery 0000000 0000
To view this company’s complete investment and acquisition history, request access »

Aevi Genomic Medicine Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Aevi Genomic Medicine‘s full profile, request access.

Request full access to PitchBook

Aevi Genomic Medicine Executive Team (10)

Name Title Board
Seat
Contact
Info
Michael Cola Chief Executive Officer, Board Member & President
Garry Neil MD Chief Scientific Officer
Nir Shapir Ph.D Senior Vice President, Research & Development and Site Head, Israel
Michael McInaw Controller

6 Former Executives

You’re viewing 4 of 10 executives. Get the full list »

Aevi Genomic Medicine Board Members (11)

Name Representing Role Since Contact
Info
Alastair Clemow Ph.D Self Board Member 000 0000
Eugene Bauer MD Self Board Member 000 0000
Joseph Grano Jr. Self Board Member 000 0000
Matthew Bayley MD Children's Hospital of Philadelphia Board Member 000 0000
Sol Barer Ph.D Self Chairman & Board Member 000 0000

6 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »